Who is sponsoring NCT06072417?

NCT06072417 is sponsored by University of Zurich.

What condition does NCT06072417 study?

NCT06072417 studies Pulmonary Vascular Disease, Pulmonary Artery Hypertension, Chronic Thromboembolic Pulmonary Hypertension.

Is NCT06072417 still recruiting?

NCT06072417 is currently status unknown. Last updated 10 October 2023.

Last reviewed 2023-10-10 · How we verify

NCT06072417

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

HA Residents With PVD, SDB Assessed at HA (2840m) vs LA (Sea Level)

Status unknown NA Last updated 10 October 2023

What this trial tests

NA trial testing Assessment without intervention at High altitude in Pulmonary Vascular Disease in 24 participants. Status unknown.

Timeline

22 September 2023

Primary endpoint
31 December 2023

31 December 2023

Quick facts

Lead sponsor	University of Zurich
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	crossover
Masking	none
Primary purpose	supportive care
Enrollment	24
Start date	22 September 2023
Primary completion	31 December 2023
Estimated completion	31 December 2023
Sites	1 location across Switzerland

Drugs / interventions tested

Assessment without intervention at High altitude
Relocation to sea level for 2 days

Conditions studied

Pulmonary Vascular Disease — all drugs for Pulmonary Vascular Disease →
Pulmonary Artery Hypertension — all drugs for Pulmonary Artery Hypertension →
Chronic Thromboembolic Pulmonary Hypertension — all drugs for Chronic Thromboembolic Pulmonary Hypertension →

Sponsor

University of Zurich

Who can join

Adults 18 to 80, any sex, with Pulmonary Vascular Disease or Pulmonary Artery Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To study the effect of relocation from 2840m (Quito) to sea level (Pedernales) in patients with pulmonary vascular diseases (PVD) defined as pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension (PH) who permanently live \>2500m on sleep disordered breathing

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other University of Zurich trials

Trials by the same sponsor.

NCT07485699 — Soy Processing and Food Allergy · NA · not yet recruiting
NCT07516912 — Evaluation of Free STI Testing Pilot Projects in Lucerne and Zurich, Switzerland · not yet recruiting
NCT07473115 — Individualized Analgesia in the Intensive Care Unit With a New Pain Assessment Bundle and Protocolized Analgesia Adjustm · not yet recruiting
NCT07524023 — Emotional-distress-based Integrated Care Programme in Patients With Stable COPD · NA · recruiting
NCT06481982 — Value of Advanced MRI Techniques in the Assessment of Endometriosis · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06072417 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Zurich
Last refreshed: 10 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06072417.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing